Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

• ClinicalTrials.gov Identifier: NCT05237960
• Recruitment Status: Recruiting
• First Posted: February 14, 2022
• Last Update Posted: March 30, 2023
• Sponsor: University of Arizona
• Collaborator: National Cancer Institute (NCI)
• Information provided by (Responsible Party): University of Arizona

Study Description

Brief Summary:

This phase IIb trial tests whether metformin works in preventing oral cancer in patients with oral leukoplakia (white patches) or erythroplakia (red patches). Metformin is in a class of drugs called biguanides. Metformin helps to control the amount of glucose (sugar) in the blood. It decreases the amount of glucose patients absorb from food and the amount of glucose made by the liver. Metformin also increases the body's response to insulin, a natural substance that controls the amount of glucose in the blood. This trial may help researchers determine if metformin can stop changes in the mouth that are related to pre-cancer growths in the mouth.

Condition or disease	Intervention/treatment	Phase
Erythroplakia; Oral Leukoplakia	Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Extended Release Metformin Hydrochloride; Drug: Placebo Administration	Phase 2

Detailed Description:

PRIMARY OBJECTIVE:

I. To determine the histological response to metformin hydrochloride (metformin) intervention in the target lesion.

SECONDARY OBJECTIVES:

I. Clinical response to metformin intervention in the target lesion. II. Effect of metformin on cell proliferation (Ki67) and its molecular targets (pS6 and nuclear YAP) in the target lesion.

III. Metformin effect on serum metabolic markers (C-peptide, glucose and HbA1c).

IV. Trough plasma metformin concentrations.

EXPLORATORY OBJECTIVES:

I. Expression of dysregulated molecular mechanisms in the target lesion, including, in order of priority, p53, PTEN, p16, EGFR, and pEGFR.

II. Immune cell infiltration and markers of inflammation in the target lesion. III. Analysis of genomic alterations in the target lesion and blood deoxyribonucleic acid (DNA).

IV. Microbiome in oral rinses.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive extended release metformin hydrochloride orally (PO) once daily (QD) for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and biopsy at baseline and week 24.

ARM II: Patients receive a placebo PO QD for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and biopsy at baseline and week 24.

After completion of study treatment, patients are followed for up to 3 weeks.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 86 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Prevention
• Official Title: M4OC-Prevent 2.0: Phase IIb Trial of Metformin for Oral Cancer Prevention
• Actual Study Start Date: November 28, 2022
• Estimated Primary Completion Date: July 31, 2026
• Estimated Study Completion Date: July 31, 2026

Arms and Interventions

Arm	Intervention/treatment
Experimental: Arm I (extended release metformin); Patients receive extended release metformin hydrochloride PO QD for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients will also undergo biopsies and blood collections on study.	Procedure: Biopsy; Undergo biopsy; Other Names: BIOPSY_TYPE; Bx; Procedure: Biospecimen Collection; Correlative studies; Other Names: Biological Sample Collection; Biospecimen Collected; Specimen Collection; Drug: Extended Release Metformin Hydrochloride; Given PO; Other Names: ER Metformin Hydrochloride; Extended-release Metformin Hydrochloride; Glucophage XR; Glumetza; Metformin Hydrochloride Extended Release
Placebo Comparator: Arm II (placebo); Patients receive a placebo PO QD for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients will also undergo biopsies and blood collections on study.	Procedure: Biopsy; Undergo biopsy; Other Names: BIOPSY_TYPE; Bx; Procedure: Biospecimen Collection; Correlative studies; Other Names: Biological Sample Collection; Biospecimen Collected; Specimen Collection; Drug: Placebo Administration; Given PO

Outcome Measures

Primary Outcome Measures :

1. Histologic response to metformin [ Time Frame: Up to 24 weeks ]
   Histologic response will be evaluated by the following criteria: complete response (CR): Complete reversal of dysplasia or hyperplasia to normal epithelium in the target lesion. Partial response (PR): Improvement of the degree of dysplasia or hyperplasia in the target lesion. No change (NC): No change in the degree of dysplasia or hyperplasia in the target lesion, anything that is not CR, PR or PD. Progressive disease (PD): Increase in the severity of grade of histology in the target lesion.

Secondary Outcome Measures :

1. Clinical response to metformin [ Time Frame: Up to 24 weeks ]
   Clinical response will be evaluated by the following criteria: CR: disappearance of all evidence of lesion(s). PR: greater than or equal to 50% reduction in the sum of the products of diameters of lesion(s) measurable at baseline. Non-measurable lesion(s) may not increase greater than or equal to 25% in size and no new lesion may appear. NC: no change in the size of the lesion(s) identified at baseline and no new lesions appearing, i.e., anything that is not CR, PR, or PD. PD: any increase greater than or equal to 25% in the product of the diameters of any lesion(s) measurable at baseline or in the estimated size of lesion(s) nonmeasurable at baseline or the appearance of an unequivocal new lesion.
2. Cell proliferation [ Time Frame: Up to 24 weeks ]
   Effect of metformin on cell proliferation (Ki67) and its molecular targets (pS6 and nuclear YAP) in the target lesion. The change (pre to post) will be compared between arms.
3. Serum metabolic markers [ Time Frame: Up to 24 weeks ]
   Metformin effect on serum metabolic markers (C-peptide, glucose and HbA1c). The change (pre to post) in serum metabolic markers will be compared between arms.
4. Plasma metformin concentrations [ Time Frame: From baseline, up to 24 weeks ]
   The plasma metformin concentrations will be determined in the pre- and post-intervention samples.

Eligibility Criteria

• Ages Eligible for Study: 21 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Participants with oral leukoplakia or erythroplakia with mild, moderate, or severe histologic dysplasia or hyperplasia at the high risk sites (e.g., floor of mouth, tongue). Lesions arising from the radiation field are excluded as study lesions.
• Measurable disease - minimum lesion size of 8x3 mm before initial biopsy
• Age >= 21 years. Adults 18-20 are not included as Canadian law prohibits purchase of cigarettes under the age of 21; investigators wish to keep criteria consistent among all trial sites. Also, smokers aged < 20 years would most likely not have oral leukoplakia
• Current and former smokers (>= 5 packs in the lifetime)
• Karnofsky performance scale >= 70%
• Leukocytes >= 3,000/microliter
• Absolute neutrophil count >= 1,000/microliter
• Platelets >= 100,000/microliter
• Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
• Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 x institutional ULN
• Estimation glomerular filtration rate (eGFR) > 45 mL/min (eGFR calculated using the equation Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] creatinine)
• Willing to use adequate contraception (barrier method, abstinence, subject or partner has had a vasectomy or partner is using effective birth control or is postmenopausal) for the duration of study participation because the effects of metformin on the developing human fetus are unknown even though it is not teratogenic in rats and rabbits at 2-6 times the maximum recommended human daily dose. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately.
• Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
• For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
• Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
• Patients on chronic suppressive antiviral therapy for herpes simplex virus (HSV) are eligible
• Ability to take oral medication
• Ability to understand and the willingness to sign a written informed consent document in English or Spanish

Exclusion Criteria:

• Patients with diabetes who are being treated with insulin or an anti-diabetic medication
• History of diabetic ketoacidosis
• Participants may not be receiving any other investigational agents within past 3 months at screeining
• History of allergic reactions attributed to compounds of similar chemical composition to metformin or prior use of metformin within the last year
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, human immunodeficiency virus (HIV) positive, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Oral carcinoma in situ from the baseline biopsy
• History of chronic alcohol use or abuse defined as any one of the following: a) average consumption of 3 or more alcohol containing beverages daily in the past 12 months; b) consumption of 7 or more alcoholic beverages within a 24 hour (hr) period in the past 12 months
• Hemoglobin A1c (HbA1c) > 8%
• Pregnancy or nursing women. Pregnant women are excluded from this study because the effects of metformin on the developing human fetus are unknown even though it is not teratogenic in rats and rabbits at 2-6 times the maximum recommended human daily dose. Because there is an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with metformin, breastfeeding should be discontinued
• Acute or chronic liver disease, evidence of hepatitis (infectious or autoimmune), cirrhosis or portal hypertension
• History of renal disease
• Have received hormone therapy, chemotherapy, immunotherapy and/or radiation for any malignancy (excluding non-melanoma skin cancer and cancers confined to organs with removal as only treatment) within the past 18 months. History of prior curatively treated cancer, including oral cancer, is allowed as long as all primary and adjuvant treatment is completed >= 18 months prior to enrollment. Ongoing adjuvant hormonal treatment (e.g., for breast cancer) is allowed.
• Current use of carbonic anhydrase inhibitors (e.g. topiramate, zonisamide, acetazolamide, or dichlorphenamide) or ranolazine

Contacts and Locations

Locations

United States, Arizona

University of Arizona Cancer Center-North Campus; Recruiting

Tucson, Arizona, United States, 85719

Contact: Shethal Bearelly 520-626-5054 sbearelly@oto.arizona.edu

Principal Investigator: Shethal Bearelly

United States, California

UC San Diego Medical Center - Hillcrest; Not yet recruiting

San Diego, California, United States, 92103

Contact: Scott M. Lippman 858-822-1222 slippman@ucsd.edu

Principal Investigator: Scott M. Lippman

United States, Florida

Moffitt Cancer Center; Recruiting

Tampa, Florida, United States, 33612

Contact: Christine H. Chung 813-745-5431 christine.chung@moffitt.org

Principal Investigator: Christine H. Chung

United States, Georgia

Emory University Hospital/Winship Cancer Institute; Not yet recruiting

Atlanta, Georgia, United States, 30322

Contact: Jennifer Gross 404-778-0278 Jhgros3@emory.edu

Principal Investigator: Jennifer Gross

United States, Louisiana

Louisiana State University; Not yet recruiting

Lafayette, Louisiana, United States, 70503

Contact: Cherie-Ann O. Nathan 318-675-6262 cherieann.nathan@lsuhs.edu

Principal Investigator: Cherie-Ann O. Nathan

United States, Michigan

University of Michigan Comprehensive Cancer Center; Not yet recruiting

Ann Arbor, Michigan, United States, 48109

Contact: Justine Moe 734-963-5963 jusmoe@med.umich.edu

Principal Investigator: Justine Moe

United States, Minnesota

University of Minnesota/Masonic Cancer Center; Not yet recruiting

Minneapolis, Minnesota, United States, 55455

Contact: Frank G. Ondrey 612-625-3200 ondre002@umn.edu

Principal Investigator: Frank G. Ondrey

United States, New York

NYU College of Dentistry; Not yet recruiting

New York, New York, United States, 10010

Contact: Alexander R. Kerr 212-998-9885 ark3@nyu.edu

Principal Investigator: Alexander R. Kerr

Canada, British Columbia

British Columbia Cancer Agency; Not yet recruiting

Vancouver, British Columbia, Canada, V5Z 4E6

Contact: Miriam Rosin 604-675-8061 mrosin@bccrc.ca

Principal Investigator: Miriam Rosin

Canada, Nova Scotia

Dalhousie University; Not yet recruiting

Halifax, Nova Scotia, Canada, B3H 4R2

Contact: Leigha Rock leigha.rock@dal.ca

Principal Investigator: Leigha Rock

Sponsors and Collaborators

University of Arizona

National Cancer Institute (NCI)

Investigators

• Principal Investigator: Scott M Lippman; University of California, San Diego Moores Cancer Center

More Information

• Responsible Party: University of Arizona
• ClinicalTrials.gov Identifier: NCT05237960
• Other Study ID Numbers: NCI-2022-00596; NCI-2022-00596 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ); Pending12 ( Other Identifier: University of Arizona Cancer Center - Prevention Research Clinic ); UAZ21-07-01 ( Other Identifier: DCP ); P30CA023074 ( U.S. NIH Grant/Contract ); UG1CA242596 ( U.S. NIH Grant/Contract )
• First Posted: February 14, 2022
• Last Update Posted: March 30, 2023
• Last Verified: March 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
• URL: https://grants.nih.gov/policy/sharing.htm

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Mouth Neoplasms; Leukoplakia; Leukoplakia, Oral; Erythroplasia; Head and Neck Neoplasms; Neoplasms by Site; Neoplasms; Mouth Diseases; Stomatognathic Diseases; Precancerous Conditions; Pathological Conditions, Anatomical; Metformin; Hypoglycemic Agents; Physiological Effects of Drugs